Array BioPharma

The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Boulder, US
Size (employees)
156 (est)
Array BioPharma was founded in 1998 and is headquartered in Boulder, US

Array BioPharma Office Locations

Array BioPharma has offices in Boulder, Houston, Morrisville, Cambridge
Boulder, US
Houston, US
Morrisville, US
Cambridge, US

Array BioPharma Metrics

Array BioPharma Summary

Market capitalization

$1.78 B

Closing share price

Array BioPharma's current market capitalization is $1.78 B.

Array BioPharma Financials

Array BioPharma's revenue is $138 M in FY, 2016 which is 165.62% increase from the previous period.
FY, 2016FY, 2015FY, 2014


$138 M$51.9 M$42.1 M

Revenue growth, %


Gross profit

$115 M$7.52 M$-3.89 M

Operating income

$-82.2 M$3.29 M$-75.6 M

Operating expense total

$220 M$130 M$118 M

Net Income

$-92.8 M$9.37 M$-85.3 M

Operating cash flow

$907 K$-12.9 M$7.86 M

Array BioPharma Market Value History

Array BioPharma Company Life

You may also be interested in